The impact of bilateral salpingo-oophorectomy on breast MRI Background parenchymal enhancement and fibroglandular tissue

European Radiology

Volumn 24, Issue 1, 2014, Pages 162-168

  Price, E R ^a   Brooks, J D ^b   Watson, E J ^b   Brennan, S B ^b   Comen, E A ^b   Morris, E A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast; Enhancement; Fibroglandular; MRI; Oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CONTRAST MEDIUM;

ADULT; ARTICLE; BACKGROUND PARENCHYMAL ENHANCEMENT; BILATERAL SALPINGO OOPHORECTOMY; BREAST; BREAST CANCER; BREAST EXAMINATION; BREAST MAGNETIC RESONANCE IMAGING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; FIBROGLANDULAR TISSUE; GENE MUTATION; HUMAN; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY;

ADULT; AGED; BREAST; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; RETROSPECTIVE STUDIES; SALPINGECTOMY;

EID: 84890431919     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-2993-9     Document Type: Article

References (22)

1. Saslow D, Boetes C, BurkeWet al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89
2. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130
3. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol : Off J Am Soc Clin Oncol 25:1329-1333
4. Morris EA (2007) Diagnostic breast MR imaging: current status and future directions. Radiol Clin N Am 45:863-880, vii
5. Kuhl CK, Bieling HB, Gieseke J et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast-enhancedMR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 203:137-144
6. Muller-Schimpfle M, OhmenhauserK, Stoll P, Dietz K, Claussen CD (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203:145-149
7. Hussain Z, Roberts N, Whitehouse GH, Garcia-Finana M, Percy D (1999) Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. B J Radiol 72:236-245
8. Graham SJ, Stanchev PL, Lloyd-Smith JO, BronskillMJ, Plewes DB (1995) Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed byMR imaging at 1.5 T. J Magn Reson Imaging : JMRI 5:695-701
9. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging-initial observations. Radiology 235:36-41
10. Harvey JA, Santen RJ, Petroni GR et al (2008) Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 15:67-73
11. Pfleiderer SO, Sachse S, Sauner D et al (2004) Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res : BCR 6:R232-R238
12. King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA (2012) Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 22:2641-2647
13. KingV,Kaplan J, PikeMC et al (2012) Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 18:527-534
14. Eng-Wong J, Orzano-Birgani J, Chow CK et al (2008) Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomark Prev : Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 17:1696-1701
15. King V, Goldfarb SB, Brooks JD et al (2012) Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 264:670-678
16. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breastMR imaging and breast cancer risk. Radiology 260:50-60
17. D'Orsi CJ, Mendelson EB, Ikeda DM et al (2003) Breast Imaging Reporting and Data System: ACR BI-RADS-Breast Imaging Atlas. American College of Radiology, Reston, VA
18. Landis JR,KochGG(1977) Themeasurement of observer agreement for categorical data. Biometrics 33:159-174
19. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87
20. Fakkert IE,MouritsMJ, Jansen L et al (2012) Breast cancer incidence after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Cancer Prev Res (Phila) 5:1291-1297
21. Berliner JL, Fay AM (2007) Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 16:241-260
22. Ciatto S, Houssami N, Apruzzese A et al (2005) Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast 14:269-275